Brief: Quantum Genomics: Results Of Phase IIb Study Of Its Firibastat Drug

Quantum Genomics SA

27/08/2021 09:59

Aug 27 (Reuters) - Quantum Genomics SA  ALQGC.PA :
    * PRESENTS RESULTS FROM PHASE IIB QUORUM STUDY OF FIRIBASTAT
IN
HEART FAILURE AT EUROPEAN SOCIETY OF CARDIOLOGY MEETING
    * FIRIBASTAT IS AS EFFICIENT AS CURRENT STANDARD OF CARE
(RAMIPRIL) IN PREVENTING DEGRADATION OF LEFT VENTRICULAR
EJECTION FRACTION (PRIMARY ENDPOINT) AFTER MYOCARDIAL INFARCTION
IN FULL STUDY POPULATION
    * FIRIBASTAT DEMONSTRATED BETTER EFFICACY COMPARED TO
RAMIPRIL IN
SEVERE PATIENTS WITH LOW EJECTION FRACTION
    * FIRIBASTAT IMPROVED BLOOD PRESSURE PROFILE IN STUDY
POPULATION
    * GOOD SAFETY PROFILE OBSERVED FROM TWO DOSES OF FIRIBASTAT

Source text for Eikon:  ID:nGNX4BmGPD 
Further company coverage:  ALQGC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))